Bone marrow-derived mesenchymal stem cells (MSCs) have been reported to migrate to 26 brain lesions of neurodegenerative diseases; however, the precise mechanisms by which 27
We recently reported that human MSCs (hMSCs) migrate to CNS lesions and prolong the 87 survival of mice infected with prion (51). In the present study we investigated factors that 88 are involved in the migration of hMSCs to brain lesions of prion diseases. 89
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MATERIALS AND METHODS

92
-8 -(Molecular Probes, Eugene, OR) (1:1000 dilution) for 30 min on ice. After washing, the 160 cells were stained with 5 µg/ml of propidium iodide (Molecular Probes) in PBS for 5 min, and 161 analyzed using an EPICS XL-ADC flow cytometer (Beckman Coulter, Miami, FL). 162
163
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) 164
Total RNA was obtained from hMSCs or from mouse brains using Trizol Reagent 165 (Invitrogen Life Technologies, Carlsbad, CA). First-strand cDNA was synthesized from 2.5 166 µg of the total RNA using a First-strand synthesis kit (Amersham Biosciences, UK) according 167 to the manufacturer's instructions. Quantitative PCR was carried out using a TaqMan assay. 168
The amplification reaction mixtures contained template cDNA, 1× pre-designed TaqMan 169
Gene Expression Assays and 1× TaqMan Universal PCR Master Mix (Applied Biosystems, 170
Foster City, CA) in a final reaction volume of 20 µl. The following TaqMan gene expression 171 assays were purchased from Applied Biosystems; human genes for PDGF-αβR (assay ID; 172 Hs00182163), CCR3 (Hs00266213), CCR4 (Hs99999919), CCR5 (Hs99999149), CX3CR1 173 (Hs00365842), CXCR3 (Hs01847760) and CXCR4 (Hs00607978), and mouse genes for 174 CCL3 (Mm00441259), CCL4 (Mm00443111), CCL5 (Mm01302427), CCL7 (Mm00443113), 175 CCL17 (Mm01244826), CX3CL1 (Mm00436454), CXCL10 (Mm00445235) and CXCL12 176 (Mm00445553). The human RNase P gene or the mouse glyceraldehyde-3-phosphate 177 dehydrogenase (GAPDH) gene was amplified as an internal marker using human RNase P 178 control reagents (Applied Biosystems, 4316844) or TaqMan rodent GAPDH control reagents 179 (Applied Biosystems, 4308313). TaqMan assays were carried out using an ABI PRISM 180 7900HT Sequence Detection System (Applied Biosystems). The amplification profiles were 181 analyzed using the threshold cycle (CT) relative quantification method, and were normalized 182 -9 -to the expression of the human RNase P control gene or the mouse GAPDH gene, which were 183 used as human and mouse reference genes as described previously (58). To determine the effects of oxygen conditions on the migration of hMSCs to brain 207 homogenates of mock-or prion-infected mice, hMSCs that were cultured under normoxic or 208 hypoxic conditions were analyzed using an in vitro migration assay. The hMSCs that were 209 pre-cultured under hypoxic conditions migrated to brain extracts of prion-infected mice more 210 efficiently than those pre-cultured under normoxic conditions (Fig. 1A) . Quantitative 211 analysis revealed that twice as many hMSCs migrated to the brain extracts of prion-infected 212 mice than to those of mock-infected mice following normoxic pre-conditioning, while 2.7 213 times more hMSCs migrated to the brain extracts of prion-infected mice following hypoxic 214 pre-conditioning (Fig. 1B) . No differences were observed in the migration of hMSCs to the 215 brain extracts of mock-infected mice between normoxic and hypoxic pre-conditioning. We 216 therefore used hMSCs that were pre-cultured under hypoxic conditions for all subsequent 217 experiments to facilitate discrimination between subtle differences in cell migration. These 218 hMSCs showed a time-dependent increase in migration for up to 24 h (Fig. 1C) , and their 219 migration increased in a brain-extract concentration-dependent manner (Fig. 1D) . Migration 220 of hMSCs to 0.01% and 0.001% brain homogenates of prion-infected mice was observed, 221 whereas only migration to 1% brain homogenates, but not to lower percentages of brain 222 extracts of mock-infected mice was observed. 223
224
Chemotactic factors involved in the migration of hMSCs 225
The chemokine CXCL12 and its receptor, CXCR4, are known to be involved in the 226 chemotactic migration of MSCs to brain lesions of neurodegenerative diseases (24, 63). 227
However, as MSCs express a variety of receptors for growth factors, chemokines and 228 -11 -cytokines that are associated with cell migration (8, 52), it was anticipated that other 229 cytokines, chemokines and growth factors also play a role in the migration of MSCs. We 230 therefore selected 10 receptors for chemokines and growth factors, and 13 of their ligands, as 231 indicated in Table 1 , and analyzed their involvement in hMSC migration using an in vitro 232 migration assay (Fig. 2) . These factors were chosen with reference to cell surface expression 233 of those receptors on MSCs in previous studies (50), and to the pathway and networks of 234 receptors and their ligands obtained using Ingenuity Pathway Analysis 5.0 (Ingenuity System 235 Inc., Redwood City, CA). The migration of hMSCs to the brain extracts of prion-infected 236 mice was significantly decreased when hMSCs were pre-treated with antibodies against 237 CCR3, CCR4, CCR5, CXCR3 and CXCR4, compared with the migration of non-treated 238 hMSCs (p < 0.05, Dunnett's tests) ( Fig. 2A) . When antibodies against the ligands of these 239 receptors were tested (Table 1) , the migration of hMSCs was significantly decreased by 240 treatment of the brain extracts with antibodies against the ligands for CCR3 (CCL5, CCL7 241 and CCL24), CCR5 (CCL3, CCL4 and CCL5), CXCR3 (CXCL10) and CXCR4 (CXCL12) 242 (p < 0.05) (Fig. 2B ). Neither the antibody against CX3CR1, nor that against its 243 corresponding ligand, CX3CL1, decreased the migration of hMSCs. In addition, the 244 antibody against CCR4 decreased hMSC migration, whereas the antibody against its ligand, 245 CCL17, did not. When the involvement of growth factors and their receptors in migration 246 was analyzed, antibodies against the PDGF-αβR or the IGF-1R did not decrease migration, 247 whereas antibodies against their respective ligands, PDGF-AB and IGF-1, did decrease 248 migration. In addition, an antibody against CCR2 or its ligand CCL2 did not decrease 249 migration, but an antibody against CCL7, another ligand for CCR2, did decrease migration. 250
Taking into account of biological relationship between the receptors and ligands that were 251 -12 -analyzed here, the migration assays suggested that at least CCR3, CCR5, CXCR3 and 252 CXCR4, and their ligands were involved in the migration of hMSCs to the brain extracts of 253 prion-infected mice. 254
255
The expression of chemokine and chemokine receptor genes. 256
We next examined the expression of chemokine genes in the brains of prion-infected mice 257 and that of chemokine receptor genes in hMSCs treated with the brain extracts of 258 prion-infected mice. For the latter analysis, hMSCs were incubated with DMEM containing 259 1% brain extracts of prion-or mock-infected mice. Twenty-four hours after incubation, total 260 RNA was recovered and gene expression was analyzed using qRT-PCR. The expression of 261 CCR3, CCR4, CCR5 and CXCR4 genes was elevated 2-to 9-fold in hMSCs treated with the 262 brain extracts of prion-infected mice compared to their expressions in hMSCs that were 263 treated with the brain extracts of mock-infected mice (Fig. 3A) . In contrast, the expression 264 of PDGF-αβR, CX3CR1 and CXCR3 genes was not up-regulated by stimulation of the 265 hMSCs with brain extracts from prion-infected mice. 266
The expression of chemokine genes in the brains of prion-infected mice or of age-matched 267 control mice was also analyzed at 120 dpi. The expression of CCL3, CCL4, CCL5 and 268 CXCL10 genes was up-regulated by 10-fold (CXCL10, CCL5) to nearly 50-fold (CCL3, 269 CCL4) in the brains of prion-infected mice (Fig. 3B ). In addition, the mRNA levels of 270 CCL7 and CCL17 (a ligand for CCR4) were moderately increased (about 3 to 6-fold) in the 271 brains of prion-infected mice. In contrast, expression of the CX3CL1 and CXCL12 genes 272
was not up-regulated. 273
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Expression of chemokine receptors on hMSCs. 275
Flowcytometric analysis and IFA were carried out to confirm the expression of chemokine 276 and growth factor receptors on hMSCs. The hMSCs treated with brain extracts of 277 mock-infected mice expressed PDGF-αβR, CCR3, CCR4, CXCR4 and CXCR3 on the cell 278 surface. Of these receptors, expression of CCR3, CCR4 and CXCR4 was increased by 279 stimulation with brain extracts of prion-infected mice, whereas no increase in expression of 280 PDGF-αβR and CXCR3 was observed. Although it is difficult to distinguish signals on the 281 plasma membrane from those in the cytoplasm using IFA, a similar tendency was observed in 282 IFA; CCR3, CCR4 and CXCR4 fluorescent signals appeared to be more intense in cells 283 treated with brain extracts of prion-infected mice than in cells treated with brain extracts of 284 mock-infected mice. In contrast to the expression of these receptors, hMSCs expressed a 285 trace level of CX3CR1, and CCR5 was not detectable on the cell surface. However, the 286 expression of CCR5 was specifically induced in response to brain extracts of prion-infected 287 mice (Fig. 4A) . The prion-specific induction of CCR5 expression was also confirmed by 288 IFA (Fig. 4B) . 289 290
Differential expression of chemokine receptors on hMSCs after transplantation into the 291 brains of prion-infected mice 292
It is known that MSCs transplanted into the left hippocampus or thalamus migrate to the 293 contralateral (right) hippocampus through the corpus callosum (3, 19, 51). Therefore, we 294 hypothesized that receptors expressed on hMSCs in the corpus callosum are possibly involved 295 in the migration of hMSCs to neuropathological lesions. We therefore transplanted hMSCs 296 into the left thalamus of prion-or mock-infected mice at 120 dpi, and analyzed the expression 297 -14 -of growth factor/chemokine receptors on hMSCs. Two days after transplantation of hMSCs 298 into the left thalamus of prion-infected mice, hMSCs in the transplanted region expressed 299 CCR1, CCR3, CCR4, CCR5, CX3CR1, CXCR3 and CXCR4 (Fig. 5A) as well as PDGF-αβR, 300
IGF-1R and CCR2 (data not shown). However, the hMSCs that were transplanted into the 301 mock-infected mice showed weak expression of these receptors except for CXCR3, 302
suggesting that the expression of these chemokine receptors was increased by stimulation 303 with factors produced in the brains of prion-infected mice. At 2 days post-transplantation, 304 hMSCs in the corpus callosum of prion-infected mice still strongly expressed CCR3, CCR5, 305 CXCR3 and CXCR4, but expression of CCR1, CX3CR1 and CCR4 appeared to be lower than 306 that on hMSCs in the transplanted area (Fig. 5B) . The expression of chemokine receptors on 307 hMSCs in the contralateral hippocampus also differed from that on hMSCs in the transplanted 308 region and in the corpus callosum; hMSCs preferentially expressed only CCR1, CX3CR1 and 309 CXCR4 in the contralateral hippocampus at one week post-transplantation (Fig. 5B) . These 310 data suggest that CCR1, CX3CR1 and CXCR4 may be associated with specific activities of 311 hMSCs after their migration to the target lesions. have been reported to be strong chemoattractants for MSC migration in vitro (42). In the 361 present study, antibodies against these two growth factors reduced hMSC migration, but 362 antibodies against their receptors did not inhibit hMSC migration despite the surface 363 expression of these receptors on hMSCs (Fig. 4) . Because of the complexity of the brain 364 extracts and the limitations of blocking experiments, the lack of inhibition by these antibodies 365 against those receptors does not necessarily mean that these ligands/receptor interactions have 366 cytokines, chemokines and growth factors, whose expression is up-regulated in the brains of 384 prion-infected mice, e.g., the CXCL10, CCL3-5 and CCL7 that we analyzed in this study, as 385 well as other factors reported previously (5, 57, 65), will stimulate hMSCs to initiate 386
migration. 387
The corpus callosum is known to be one of the sites through which MSCs transplanted into 388 one hemisphere migrate to the contralateral hemisphere (3, 19). We recently reported that 389 -18 -hMSCs transplanted into the left thalamus of prion-infected mice were detected in the corpus 390 callosum, the contralateral hippocampus and thalamus 2 days after transplantation (51). This 391 result suggests that the hMSCs that were detected in the corpus callosum were migrating to 392 the brain lesions in the contralateral hemisphere. Based on this idea, we therefore analyzed 393 the expression of chemokine receptors on hMSCs that were transplanted into prion-infected 394 mice. Interestingly, in agreement with the interpretation of the in vitro migration assays, 395 hMSCs in the corpus callosum clearly expressed CCR3, CCR5, CXCR3 and CXCR4 2 days 396 after transplantation (Fig. 5B) , suggesting the involvement of these chemokine receptors in 397 the migration of hMSCs in vivo. In contrast to hMSCs in the corpus callosum, hMSCs that 398 had migrated to the contralateral hippocampus showed reduced expression of CCR3, CCR5 399 and CXCR3, whereas strong expression of CXCR4 was still observed. These results suggest 400 that CXCR4 plays a role not only in migration, but also in regulating hMSC activity following 401 chemotactic migration. A role in the regulation of hMSC activity following chemotactic 402 migration may also apply to the expression of CCR1 and CX3CR1; the weak expression of 403 CCR1 and CX3CR1 on hMSCs in the corpus callosum (Fig. 5B) appears to be consistent with 404 the results of the in vitro migration assay (Fig. 2) . However, in contrast, these receptors 405 were clearly expressed on hMSCs in the transplanted thalamus at 2 days post-transplantation 406 and in the contralateral hippocampus of prion-infected mice a week after transplantation, 407
implying that CCR1 and CX3CR1 may play a role in regulating MSC activity after migration 408 to the targeted site. To be continued
